PSNL Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of -149.38% compared to Personalis, Inc.'s net margin of -82.06%. Personalis, Inc.'s return on equity of -39.33% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Personalis, Inc. has a consensus price target of $11.29, signalling upside risk potential of 26.66%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.13 which suggests that it could grow by 9.6%. Given that Personalis, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Personalis, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Personalis, Inc. has a beta of 1.980, which suggesting that the stock is 97.958% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Personalis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Personalis, Inc. quarterly revenues are $14.5M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Personalis, Inc.'s net income of -$21.7M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Personalis, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis, Inc. is 10.88x versus 14.16x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -149.38% compared to Personalis, Inc.'s net margin of -735.19%. Personalis, Inc.'s return on equity of -39.33% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Personalis, Inc. has a consensus price target of $11.29, signalling upside risk potential of 26.66%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $23.86 which suggests that it could grow by 82.95%. Given that Intellia Therapeutics, Inc. has higher upside potential than Personalis, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Personalis, Inc..

Personalis, Inc. has a beta of 1.980, which suggesting that the stock is 97.958% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.103, suggesting its more volatile than the S&P 500 by 110.271%.

Personalis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Personalis, Inc. quarterly revenues are $14.5M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Personalis, Inc.'s net income of -$21.7M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Personalis, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis, Inc. is 10.88x versus 23.76x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Biosciences of California, Inc. has a net margin of -149.38% compared to Personalis, Inc.'s net margin of -90.43%. Personalis, Inc.'s return on equity of -39.33% beat Pacific Biosciences of California, Inc.'s return on equity of -389.62%.

Personalis, Inc. has a consensus price target of $11.29, signalling upside risk potential of 26.66%. On the other hand Pacific Biosciences of California, Inc. has an analysts' consensus of $2.50 which suggests that it could grow by 48.81%. Given that Pacific Biosciences of California, Inc. has higher upside potential than Personalis, Inc., analysts believe Pacific Biosciences of California, Inc. is more attractive than Personalis, Inc..

Personalis, Inc. has a beta of 1.980, which suggesting that the stock is 97.958% more volatile than S&P 500. In comparison Pacific Biosciences of California, Inc. has a beta of 2.267, suggesting its more volatile than the S&P 500 by 126.686%.

Personalis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Biosciences of California, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis, Inc. pays -- of its earnings as a dividend. Pacific Biosciences of California, Inc. pays out -- of its earnings as a dividend.

Personalis, Inc. quarterly revenues are $14.5M, which are smaller than Pacific Biosciences of California, Inc. quarterly revenues of $44.6M. Personalis, Inc.'s net income of -$21.7M is higher than Pacific Biosciences of California, Inc.'s net income of -$40.4M. Notably, Personalis, Inc.'s price-to-earnings ratio is -- while Pacific Biosciences of California, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis, Inc. is 10.88x versus 3.15x for Pacific Biosciences of California, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -149.38% compared to Personalis, Inc.'s net margin of -29.42%. Personalis, Inc.'s return on equity of -39.33% beat Twist Bioscience Corp.'s return on equity of -16.63%.

Personalis, Inc. has a consensus price target of $11.29, signalling upside risk potential of 26.66%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $49.89 which suggests that it could fall by -4.96%. Given that Personalis, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Personalis, Inc. is more attractive than Twist Bioscience Corp..

Personalis, Inc. has a beta of 1.980, which suggesting that the stock is 97.958% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.240, suggesting its more volatile than the S&P 500 by 124.046%.

Personalis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Personalis, Inc. quarterly revenues are $14.5M, which are smaller than Twist Bioscience Corp. quarterly revenues of $103.7M. Personalis, Inc.'s net income of -$21.7M is higher than Twist Bioscience Corp.'s net income of -$30.5M. Notably, Personalis, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis, Inc. is 10.88x versus 8.12x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.